“RCL-Pooling Assay”: A Simplified Method for the Detection of Replication-Competent Lentiviruses in Vector Batches Using Sequential Pooling
- 22 January 2016
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 27 (2) , 202-210
Abstract
Nonreplicative recombinant HIV-1-derived lentiviral vectors (LV) are increasingly used in gene therapy of various genetic diseases, infectious diseases, and cancer. Before they are used in humans, preparations of LV must undergo extensive quality control testing. In particular, testing of LV must demonstrate the absence of replication-competent lentiviruses (RCL) with suitable methods, on representative fractions of vector batches. Current methods based on cell culture are challenging because high titers of vector batches translate into high volumes of cell culture to be tested in RCL assays. As vector batch size and titers are continuously increasing because of the improvement of production and purification methods, it became necessary for us to modify the current RCL assay based on the detection of p24 in cultures of indicator cells. Here, we propose a practical optimization of this method using a pairwise pooling strategy enabling easier testing of higher vector inoculum volumes. These modifications significantly decrease material handling and operator time, leading to a cost-effective method, while maintaining optimal sensibility of the RCL testing. This optimized “RCL-pooling assay” ameliorates the feasibility of the quality control of large-scale batches of clinical-grade LV while maintaining the same sensitivity.Keywords
This publication has 23 references indexed in Scilit:
- Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic LeukodystrophyScience, 2013
- Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich SyndromeScience, 2013
- Large-Scale Manufacture and Characterization of a Lentiviral Vector Produced for Clinical Ex Vivo Gene Therapy ApplicationHuman Gene Therapy, 2011
- Replication-competent Lentivirus Analysis of Clinical Grade Vector ProductsMolecular Therapy, 2011
- Biochemical Correction of X-CGD by a Novel Chimeric Promoter Regulating High Levels of Transgene Expression in Myeloid CellsMolecular Therapy, 2011
- Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemiaNature, 2010
- Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked AdrenoleukodystrophyScience, 2009
- A replication competent lentivirus (RCL) assay for equine infectious anaemia virus (EIAV)-based lentiviral vectorsGene Therapy, 2005
- Product-Enhanced Reverse Transcriptase Assay for Replication-Competent Retrovirus and Lentivirus DetectionHuman Gene Therapy, 2005
- Restricted expression of human T-Cell leukemia-lymphoma virus (HTLV) in Transformed human umbilical cord blood lymphocytesVirology, 1983